What was the primary purpose of this $30 billion debt issuance?

The primary purpose of the $30 billion senior unsecured notes offering was to fund a portion of the cash consideration required for AbbVie's acquisition of Allergan plc, as well as to cover related transaction fees and expenses.

What are the key terms of the notes issued?

The notes consist of various tranches with different maturity dates (ranging from 2021 to 2049) and interest rates. Some are floating rate notes tied to LIBOR, while others are fixed-rate notes with coupon rates ranging from 2.150% to 4.250%. They are unsecured and rank equally with AbbVie's other senior unsecured debt.

What happens if the acquisition of Allergan does not go through?

If the acquisition of Allergan is not consummated by January 30, 2021, or if AbbVie decides not to pursue the acquisition before that date, AbbVie is obligated to redeem all outstanding notes at a special mandatory redemption price of 101% of the principal amount, plus any accrued and unpaid interest.

How does this offering impact AbbVie's existing credit facilities?

Following the closing of the notes offering, AbbVie reduced its outstanding bridge credit facility by approximately $7.8 billion (from an initial amount of $10 billion, with $2.2 billion remaining), as net proceeds from the note issuance were used to pay down this facility.

ABBV 8-K: Material Agreements & Financial Events

Summary

AbbVie Inc. has reported the completion of a significant senior unsecured notes offering, raising an aggregate principal amount of $30 billion. This substantial debt issuance was undertaken in connection with AbbVie's previously announced acquisition of Allergan plc. The net proceeds are earmarked to fund a portion of the cash consideration for the Allergan acquisition, along with associated fees and expenses, with any remaining funds designated for general corporate purposes. This offering diversifies AbbVie's debt maturity profile, with notes ranging from short-term floating rate notes due in 2021 to long-term fixed-rate notes maturing in 2049. The filing also details a registration rights agreement to facilitate the potential exchange of these notes. Investors should note that the acquisition of Allergan is a key contingency, with provisions for the mandatory redemption of these notes should the acquisition not be consummated by a specified date.

Key Highlights

1AbbVie Inc. successfully completed a $30 billion offering of senior unsecured notes on November 21, 2019.
2The proceeds from the note offering are primarily intended to finance the acquisition of Allergan plc.
3The notes issued have varying maturity dates, ranging from 2021 to 2049, including both fixed and floating rate instruments.
4The issuance is governed by a base indenture and a supplemental indenture, with the notes ranking equally with other senior unsecured indebtedness.
5A mandatory redemption clause is in place, requiring AbbVie to repurchase all outstanding notes at 101% of principal plus accrued interest if the Allergan acquisition is not completed by January 30, 2021.
6The company has entered into a registration rights agreement to facilitate the exchange of these notes.
7The offering resulted in a reduction of AbbVie's outstanding bridge credit facility.

AbbVie Inc. 8-K Report, Material Agreement (Nov 26, 2019)

Summary

Key Highlights

Frequently Asked Questions